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The functional conversion of white adipose tissue
(WAT) into a tissue with brown adipose tissue
(BAT)-like activity, often referred to as ‘‘browning,’’
represents an intriguing strategy for combating
obesity and metabolic disease. We demonstrate
that thyroid hormone receptor (TR) activation by a
synthetic agonist markedly induces a program of
adaptive thermogenesis in subcutaneous WAT that
coincides with a restoration of cold tolerance to
cold-intolerant mice. Distinct from most other
browning agents, pharmacological TR activation
dissociates the browning of WAT from activation of
classical BAT. TR agonism also induces the brown-
ing of white adipocytes in vitro, indicating that TR-
mediated browning is cell autonomous. These data
establish TR agonists as a class of browning
agents, implicate the TRs in the browning of WAT,
and suggest a profound pharmacological potential
of this action.INTRODUCTION
Obesity is an accelerating worldwide health crisis associated
with co-morbidities that include diabetes, hyperlipidemia, and
hypertension. Obesity is caused by chronic intake of excess en-
ergy relative to expenditure, which becomes stored as lipid in
white adipose tissue (WAT) and leads to its expansion (Trayhurn
and Beattie, 2001). While nearly everyone is familiar with WAT,
typically referred to simply as ‘‘fat,’’ there is less appreciation
for brown adipose tissue (BAT), which has the unique capacity
to conduct non-shivering adaptive thermogenesis (NSAT), the
conversion of excess energy to heat.
Since BAT-mediated adaptive thermogenesis is inherently
anti-obesogenic (Lowell et al., 1993), there has long been an in-1528 Cell Reports 13, 1528–1537, November 24, 2015 ª2015 The Auterest in harnessing this action to treat obesity. However, until
recently, it was generally accepted that adult humans did not
possess brown fat (Cannon and Nedergaard, 2004). Instead, it
was questioned whether WAT could be induced to become
more BAT-like (Tiraby and Langin, 2003) to increase energy
expenditure. The prospect of achieving this was bolstered by
the appearance of BAT-like, or ‘‘beige,’’ cells in WAT depots in
response to cold exposure or treatment with b-adrenergic ago-
nists (Guerra et al., 1998; Cousin et al., 1992). Although tanta-
lizing, the physiological relevance of beige cells was unclear,
and it was not apparent how to exploit this effect clinically
(Arch, 2008).
Two events renewed interest in utilizing adaptive thermogene-
sis to combat obesity. First, several studies have established the
existence of active brown fat in adult humans (Sidossis and Ka-
jimura, 2015; Nedergaard et al., 2007). Second, several contem-
porary reports demonstrated the ability to impart BAT-like func-
tion to WAT depots in rodents, a process often referred to as
‘‘browning’’ (Harms and Seale, 2013). While these examples es-
tablished induction of BAT-like adaptive thermogenesis in WAT
can have anti-obesogenic and anti-diabetic effects, the magni-
tude of these effects have generally been modest despite the
use of genetically engineered mice, leaving the pharmacological
potential of browning (Nedergaard and Cannon, 2014) unclear.
It is well established that thyroid hormone receptor (TR)
signaling regulates thermogenesis, body temperature (Silva,
1995), and energy balance (Grover et al., 2004). In both humans
and mice, hypothyroidism is associated with hypersensitivity to
cold, while hyperthyroid individuals have difficulty tolerating heat
(Melish, 1990). Although TR signaling has been linked to BAT
development (Hall et al., 2010), the relationship between TR acti-
vation and thermogenesis is complex and has not been fully
resolved. Here, we report TR activation by the synthetic agonist
GC-1elicits aBAT-likeprogramofadaptive thermogenesis insub-
cutaneousWAT (scWAT). This action, which is accompanied by a
marked increase inmetabolism, fat loss, and increasedcold toler-
ance, suggests browning of WAT may represent an unappreci-
ated component of TR-induced thermogenesis.thors
Figure 1. The TR Agonist GC-1 Induces Adaptive Thermogenesis and Increases Respiration in scWAT and Isolated White Adipocytes
(A–C) Male ob/ob mice were fed a diet either containing GC-1 (3 mg/kg diet) or without for 21 days (n = 4–5). Thermogenic gene expression in BAT (A), scWAT (B),
and epiWAT (C) was determined with RT-PCR. Values were normalized to b-actin.
(D) Representative immunoblot and quantification of UCP1 protein expression in scWAT (n = 4–5). a-tubulin was used as a loading control.
(E) H&E staining of epiWAT, scWAT, and BAT from ob/ob mice following GC-1 treatment. Scale bar, 100 mm.
(F) UCP1 immunohistochemistry of representative sections of BAT, scWAT, and epiWAT of control and GC-1 treated mice. Scale bar, 100 mm.
(G) Mitochondrial DNA content relative to genomic DNA in epiWAT, scWAT, and BAT (n = 4–5).
(H) Citrate synthase activity in epiWAT, scWAT, and BAT (n = 4–5).
(I–K) Primary stromal vascular cells isolated from scWAT were grown to confluence and then stimulated to differentiate with dexamethasone, insulin, iso-
butulmethylxanthine, and rosiglitazone for 2 days. Thermogenic gene expression of cultured adipocytes treated with 100 mMGC-1 or vehicle between days 6–12,
2–12, or 0–12 (n = 4) (I). UCP1 immunofluorescence (J) and cellular respiration (K) of white adipocytes treated with GC-1 or vehicle from days 0–12 (n = 4). DAPI,
blue; UCP1, red. Scale bar, 10 mm. Leak and maximum respiration rates were measured following the addition of oligomycin and FCCP, respectively.
Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.RESULTS
The TR Agonist GC-1 Elicits a BAT-like Program of
Adaptive Thermogenesis in scWAT of ob/ob Mice
To explore how TR agonists induce thermogenesis in vivo, we
treated genetically obese (ob/ob) mice with the synthetic agonist
GC-1 and profiled changes in the expression of adaptive thermo-Cell Repgenesis genes and mitochondrial function in BAT, epididymal
WAT, and scWAT depots (Figures 1A–1C). Surprisingly, GC-1
significantly repressed all markers in BAT (Figure 1A). In contrast,
the expression of all genes was strongly induced in scWAT, with
levels of Ppargc1a, Elovl3, Cidea, Dio2, Cox5a, and Cebpb
increased over 10-fold, and Ucp1 levels increased over 100-
fold (Figure 1B). An estimate of absolute transcript levelsorts 13, 1528–1537, November 24, 2015 ª2015 The Authors 1529
suggested that, following GC-1 treatment, Ucp1mRNA levels in
scWAT were similar to BAT (Figure S1B). In epididymal WAT,
Ucp1 levels were also increased, although expression of all other
genes in the thermogenic program were either decreased or
unchanged (Figure 1C). GC-1 did alter expression levels of
genes implicated in muscle-mediated thermogenesis, although
expression of other genes including Ucp1 was unchanged and
the magnitude of the observed changes was small relative to
the alterations seen in scWAT and BAT (Figure S1A). These
data suggest the TR agonist GC-1 induces the adaptive thermo-
genesis program in scWAT.
We next investigated how GC-1 affected UCP1 protein levels
in the various adipose tissue depots. While UCP1 protein levels
were unaltered in BAT, the effect in scWAT was striking. UCP1
protein, which was undetectable in the scWAT of untreated
mice, increased at least 100-fold, reaching a level equivalent to
40% of that found in BAT (Figures 1D and S1C). UCP1 levels
were undetectable in epididymal WAT of both treated and un-
treated animals. Further, histological examination of adipose tis-
sue depots revealed remarkable morphological changes in the
scWAT of GC-1 treated mice (Figure 1E). Subcutaneous white
adipocytes of treated mice were smaller, contained multilocular
lipid droplets, and expressed UCP1 (Figure 1F), which are all
features common to brown adipocytes (Cinti et al., 2001).
Conversely, BAT of treated mice appeared to become more
white-like, suggesting decreased BAT activity. Adipocytes of
epididymal WAT exhibited little morphological change. To inves-
tigate changes in the metabolic parameters of various adipose
tissue depots, we measured mitochondrial DNA content and cit-
rate synthase activity. Following GC-1 treatment, mitochondrial
DNA and citrate synthase increased substantially in scWAT (Fig-
ures 1G and 1H), but not epididymal WAT or BAT. Collectively,
GC-1 induces genes involved in adaptive thermogenesis, in-
duces mitochondrial biogenesis, increases UCP1 protein, and
elicits morphological changes in scWAT consistent with a white
to brown-like conversion.
WAT Browning by GC-1 Is Cell Autonomous
To test whether the induction of adaptive thermogenesis was a
direct action of GC-1 on adipocytes, we examined the ability of
GC-1 to increase respiration and induce browning in primary ad-
ipocytes derived from mouse scWAT. Cells were treated with
GC-1 over different time periods during adipogenic differentia-
tion. All treatments robustly induced thermogenic genes, with
longer treatments tending to increase expression levels more
highly (Figure 1I). In primary adipocytes treated with GC-1 during
the entire course of differentiation, UCP1 and DIO2 expression
levels were increased over 7,000-fold and immunofluorescence
staining revealed a striking proliferation of UCP1-positive mito-
chondria (Figure 1J). Respiration (basal, leak, and maximal)
also increased 2-fold in cells treated similarly (Figure 1K).
Together, these results reveal TR activation increases respiration
in white adipocytes in a cell-autonomous fashion.
GC-1-Induced Browning of scWAT Coincides with
Marked Thermogenesis and Metabolic Elevation
Almost universally, reports of browning suggest that WAT-
mediated thermogenesis elicits anti-obesity and anti-diabetic1530 Cell Reports 13, 1528–1537, November 24, 2015 ª2015 The Auactions (Harms and Seale, 2013). To examine the metabolic ef-
fects that coincided with browning, we monitored body tem-
perature and metabolic rate after GC-1 treatment. GC-1 raised
metabolic rate by nearly 60% (Figures 2A and 2B) and
increased body temperature by 3.8C (Figure 2C), an increase
that was readily apparent when handling animals. The induction
of thermogenesis was accompanied by marked weight and fat
loss (Figures 2D and 2E). GC-1 treatment did not alter food
intake, and treated mice were marginally less active than un-
treated controls (Figures S2A and S2B), indicating weight loss
resulted solely from increased metabolic rate. Lean mass
increased following GC-1 treatment (Figure 2F), indicating
weight loss was due exclusively to a loss of adiposity. GC-1
treatment also led to a substantial decrease in the respiratory
exchange ratio (RER), with values approaching the theoretical
minimum of 0.7 (Figure 2G), indicating that GC-1 elicited a sub-
stantial shift in substrate utilization from carbohydrates to fatty
acids. The change in RER is consistent with reports demon-
strating that uncoupling of oxidative phosphorylation by either
chemical uncouplers (Goldgof et al., 2014) or NSAT (Nguyen
et al., 2011) increases the oxidation of fatty acids relative to
carbohydrates.
To determine whether GC-1-induced thermogenesis affected
insulin sensitivity and glycemic control, we conducted a hyperin-
sulinemic-euglycemic clamps study as well as a glucose toler-
ance test. GC-1 treatment normalized fasting glucose levels
(Figure 2H), increased glucose infusion rate (Figure 2I), and
improved glucose disposal rate, basal glucose production, and
hepatic glucose disposal (Figures 2J, S2C, and S2D), all indica-
tive of substantially increased insulin sensitivity. GC-1 treated
mice also exhibited markedly improved glycemic control (Fig-
ures 2K and 2L). Collectively, these results suggest TR activation
by GC-1 induces a thermogenic program that ameliorates
obesity and insulin resistance.
GC-1 Induces Adaptive Thermogenesis in scWAT of DIO
Mice
In addition to defects in BAT function, the leptin deficiency of ob/
ob mice perturbs numerous endocrine functions, which prompt
questions about thyroid status (Ohtake et al., 1977). To explore
the generality of the results obtained with ob/ob mice, we inves-
tigated the effects of GC-1 in diet-induced obese (DIO) C57
mice. GC-1-induced thermogenesis in DIO mice, as indicated
by increased metabolic rate (Figures S2E and S2F), increased
body temperature (Figure S2G) and fat loss (Figure S2H). Similar
to the findings in ob/obmice, genes involved in adaptive thermo-
genesis were generally increased in scWAT of agonist-treated
mice (Figure S2I), while expression of thermogenic genes
decreased in BAT (Figure S2J). UCP1 protein, which was unde-
tectable in scWAT of vehicle-treated mice, increased at least
17-fold following GC-1 treatment (Figure S2K). Similar to effects
observed in ob/ob mice, BAT levels of UCP1 protein were un-
changed (Figures S1C and S2L), despite decreased mRNA
levels. Mitochondrial DNA increased in scWAT of mice treated
with GC-1, but was unaltered in BAT (Figure S2M). Hyperglyce-
mia of DIO mice was completely normalized following GC-1
treatment, and glucose tolerance was markedly increased (Fig-
ures S2N and S2O).thors
A B C D
E F G H I
J K L
Figure 2. GC-1-Mediated Browning of WAT Coincides with Supraphysiological Thermogenesis In Vivo
(A) Energy expenditure of GC-1 treated and untreated control (ob/ob) mice was measured by indirect calorimetry at 15-min intervals over 4 days (n = 4).
(B) Average day and night metabolic rates between days 12 and 14 (n = 4).
(C) Body temperature of GC-1 treated and untreated control mice after 21 days (n = 5).
(D) Representative image of GC-1 treated (right) and untreated (left) control ob/ob mice after 21 days.
(E and F) Body fat (E) and lean mass (F) of GC-1 treated and untreated control mice monitored over the course of the treatment by MRI. Fat and lean mass are
expressed as absolute weight (n = 4–5).
(G) Respiratory exchange ratio (RER) of GC-1 treated and untreated control mice was measured at 15 min intervals.
(H) Fasting blood glucose in ob/ob mice treated with vehicle or GC-1 for 10–12 days (n = 6).
(I and J) Hyperinsulinemic-euglycemic clamps were performed following 10–12 days of treatment with vehicle or GC-1 (n = 6). Glucose infusion rate (GIR) (J) and
glucose disposal rate (GDR) (K) is expressed as mg/mouse/min.
(K and L) Glucose tolerance tests (GTT) performed on GC-1 treated and untreated control ob/ob mice assessed following 20 days of treatment (n = 5–6). (M) Area
under curve (AUC) values from (L).
Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.GC-1-Mediated Adaptive Thermogenesis Is
Independent of BAT Activity
Given the magnitude of GC-1-induced thermogenesis and the
high capacity of BAT to mediate thermogenesis in mice, we felt
it was important to ask whether BAT contributed to the thermo-
genic actions of GC-1. We used positron emission tomography-
computed tomography (PET-CT) imaging to examine the effects
of GC-1 treatment on glucose metabolism in BAT and other
peripheral tissues. In untreated mice, 18F-FDG (FDG) uptake in
intrascapular BAT was readily apparent (Figure 3A). Following
GC-1 treatment, however, FDG uptake in intrascapular BAT
became indistinguishable from uptake in surrounding tissue,
suggesting that GC-1 strongly decreases the metabolic activity
of intrascapular BAT. Instead, GC-1 treated mice exhibited
diffuse FDG uptake into extra-abdominal regions correspondingCell Repto scWAT. FDG uptake into equivalent regions of untreated mice
was undetectable. Similar changes in glucose metabolism were
observed during the hyperinsulinemic-euglycemic clamp study.
Under hyperinsulinemic conditions, 14C-deoxyglucose uptake
into scWAT increased significantly in GC-1 treated mice, while
glucose uptake into BAT was decreased (Figure 3B). To more
firmly establish that BAT did not contribute to TR-mediated ther-
mogenesis, GC-1 was administered to ob/ob and DIO mice in
which intrascapular BAT activity was ablated by surgical dener-
vation. While denervation reduced the expression of thermo-
genicmarkers in BAT (Figure S3A), GC-1 treatment induced ther-
mogenic gene expression in scWAT (Figure S3B) and resulted in
weight (Figure S3C) and fat loss (Figures 3C and S3D) and body
temperature elevation (Figures 3D and S3E) that was indistin-
guishable between BAT-denervated mice and sham treatedorts 13, 1528–1537, November 24, 2015 ª2015 The Authors 1531
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Figure 3. GC-1-Induced Thermogenesis Is Independent of BAT Activity, yet Requires UCP1
(A) Representative 18F-FDG PET-CT image of GC-1 treated (right) and untreated control (left) ob/ob mice. White arrowheads denote iBAT, and asterisks (*)
represents an extra-abdominal regions corresponding to scWAT.
(B) 14C-deoxyglucose uptake in scWAT and BAT of GC-1 treated and untreated control mice measured during the hyperinsulinemic-euglycemic clamps (n = 6).
(C and D) Male ob/ob mice were subject to either BAT denervation surgery or a sham operation. Following which, they were fed a standard chow diet with or
without GC-1 for 21 days (n = 6 per sham group; n = 3 per BAT denervated group). Change in fat mass expressed relative to initial fat mass in BAT-denervated and
sham-treated mice during GC-1 treatment (C) and final body temperature of BAT-denervated and sham mice with and without GC-1 (D) are shown.
(E–G) Ucp1/ and littermate controls were treated with GC-1 via injection for 14 days (n = 5–7). Metabolic rate (E and F) and final body temperature (G) of wild-
type and Ucp1/ mice are shown.
(H–J) SVFs from WT and Ucp1/ mice were differentiated with GC-1 or vehicle (n = 4–5). Relative gene expression determined by RT-PCR 12 days after the
initiation of differentiation (H) is shown. Oxygen consumption was performed under basal conditions, following the addition of oligomycin (i), FCCP (ii), and
antimycin A + rotenone (iii) (I and J).
Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 comparison of GC-1 treated versus untreated. yp < 0.05, yyp < 0.01, yyyp < 0.001 comparison Ucp1/
versus littermate controls. See also Figure S3.controls, indicating intrascapular BAT does not measurably
contribute to the metabolic effects elicited by GC-1.
GC-1-Mediated Thermogenesis Is Ucp1 Dependent
In order to address whether the ability of GC-1 to induce
thermogenesis was an adipose-specific effect, we explored1532 Cell Reports 13, 1528–1537, November 24, 2015 ª2015 The Auwhether GC-1 induced thermogenesis in Ucp1/ mice,
which cannot evoke any NSAT. As expected, GC-1 treatment
of control animals induced thermogenesis, as indicated by
increased metabolic rate (Figures 3E and 3F) and increased
body temperature (Figure 3G). However, GC-1 failed to elicit
either effect in Ucp1/ animals, indicating Ucp1 is required forthors
TR-agonist-induced thermogenesis (Figures 3E–3G). In order to
test whether the ability of GC-1 to induce browning in vitro was
also Ucp1 dependent, we treated white adipocytes derived
from either Ucp1/ mice or control animals with the agonist.
Although the gene expression program induced by GC-1 was
nearly identical in Ucp1/ derived adipocytes and control cells
(Figure 3H), the ability of GC-1 to increase respiration (basal and
leak) was lost in cells lacking Ucp1 (Figures 3I and 3J). Thus, the
ability of GC-1 to induce both browning in vitro and thermogen-
esis in vivo requires Ucp1.
GC-1-Induced Browning Is Not due to Fever
Cold results in increased sympathetic nervous system (SNS)
outflow to adipose tissues, leading to increased BAT activity
and WAT browning. It has been suggested that WAT browning
is simply a secondary effect of making the mice cold, either by
altering the insulating properties of the skin or fur or by inducing
a fever (Lo´pez et al., 2010; Nedergaard and Cannon, 2014). If
increasedmetabolic rate with GC-1 was due to a direct induction
of adaptive thermogenesis in scWAT, increased thermogenic
capacity and increased cold tolerance would be expected.
Conversely, if WAT browning by GC-1 was a secondary effect
of fever or reduced insulation, impaired cold tolerance would
be anticipated. Thus, we tested whether GC-1 treatment of ob/
ob mice improved or impaired cold tolerance. Almost immedi-
ately upon exposure to 4C, untreated mice exhibited pro-
nounced shivering and piloerection and body temperature
decreased sharply (Figure 4A). Conversely, GC-1 treated ani-
mals experienced no decrease in body temperature after 15 hr
at 4C. Remarkably, treated animals exhibited no apparent shiv-
ering or piloerection, suggesting that the adaptive thermogene-
sis program elicited by GC-1 obviated the need for shivering,
generally a key component of heat generation in response to
cold (Nedergaard and Cannon, 2014). We also looked at norepi-
nephrine levels in WAT and BAT and found that levels decreased
substantially in both tissues (Figure 4B) following GC-1 treat-
ment. We also tested the effects of GC-1 on Ucp1/ mice,
which cannot induce NSAT. In stark contrast to the effects
observed in ob/ob mice, GC-1 treatment of Ucp1/ mice
impaired cold tolerance as indicated by a marked decrease in
body temperature when exposed to 4C (Figure 4C). These
data strongly suggest Ucp1, and its induction in peripheral tis-
sues (namely WAT), is required for increased cold tolerance,
and in the absence of this effect, the increased temperature
set-point observed with GC-1 treatment reduces cold tolerance.
These results further suggest WAT browning induced by GC-1
is not simply a secondary effect of fever or altered insulating
capacity.
TR Activation Reduces the Requirement for SNS/b-AR
Stimulation to Induce Browning
The most well established mechanism of WAT browning is via
activation of the b-adrenergic receptors (b-AR). To explore the
relationship between GC-1-induced browning and b-AR
signaling, we first examined the effect of GC-1 on mice at ther-
moneutrality, conditions where b-AR stimulation of adipose
tissues is minimal. At thermoneutrality, GC-1 evoked thermo-
genesis, as indicated by increased metabolic rate (Figures 4DCell Repand 4E), elevated body temperature (Figure 4F), changes in
gene expression (Figure 4G), and scWAT morphology (UCP1+
multilocular cells) (Figure 4H), consistent with browning. We
next investigated how b-AR blockage affected the ability of
GC-1 to induce thermogenesis and browning. Treatment of
mice with the b-AR blocker propanolol did not affect the ability
of GC-1 to increase metabolic rate (Figures 4I and 4J) and
body temperature (Figure 4K), although themagnitude of brown-
ing, as indicated by morphological changes (UCP1+ multilocular
cells) (Figure 4L) and gene expression (Figure 4M) in WAT, was
decreased in propranolol-treated mice. We next explored the
necessity of b-AR signaling for TR-mediated browning in vitro.
In cultured white adipocytes, norepinephrine increased Ucp1
levels by 100-fold. As expected, this effect was largely lost
when b-AR signaling was blocked by the PKA inhibitor H-89 (Fig-
ure 4N). While GC-1 also robustly induced Ucp1 levels, this in-
duction was not affected by PKA inhibition. Collectively, these
data indicate GC-1 greatly reduces the necessity of b-AR stimu-
lation to induce WAT browning, either by strongly potentiating
b-AR signaling or via an alternative mechanism (Ye et al.,
2013), and establishes TR agonists as browning agents.
WATBrowning Is Not aCommonEffect of All TR agonists
In order to see whether WAT browning was a common effect of
all TR agonists, we tested the ability of the agonist KB2115 to
induce thermogenesis and browning. While KB2115 slightly
increased metabolic rate (Figures S4A and S4B), no increase in
body temperature was observed (Figure S4C). In scWAT,
KB2115 induced thermogenic genes (Figure S4D) at a level far
lower than that demonstrated by GC-1. Further, in a related
study we found that KB2115 does not elicit any of the anti-dia-
betic actions observed with GC-1 treatment (Martago´n et al.,
2015). Thus, the potential to induce browning and concomitant
thermogenesis, at least at the magnitude observed with GC-1,
is not a common feature of all TR agonists.
DISCUSSION
We believe these data clearly establish that pharmacological
activation of TRs can elicit profound changes in white adipocytes
in vivo and in vitro consistent with a white to brown-like func-
tional conversion. This effect is restricted to scWAT, with no ev-
idence of browning in epididymal WAT, supporting the idea that
WAT browning is largely a subcutaneous phenomenon (Wang
et al., 2013). While many studies have now demonstrated the
ability to induce a BAT-like program of thermogenesis in WAT
depots (Harms and Seale, 2013), the metabolic changes that
have accompanied most demonstrations of WAT browning
have beenmodest, leading to questions about the pharmacolog-
ical potential of this action (Nedergaard and Cannon, 2014).
However, we believe our data demonstrate that WAT browning,
if affected to the magnitude observed with GC-1, can indeed
afford substantial anti-obesity and anti-diabetic effects.
Increased glucose uptake in scWAT, observed via PET imaging
and during the hyperinsulinemic-euglycemic clamp study, dem-
onstrates that scWAT contributes to the anti-diabetic actions
of GC-1 by mediating increased glucose disposal. Increased
respiration, observed in cultured adipocytes, demonstrates TRorts 13, 1528–1537, November 24, 2015 ª2015 The Authors 1533
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Figure 4. TR Activation Reduces the Requirement for SNS/b-AR Stimulation to Induce Browning
(A) Cold challenge performed on ob/ob mice were treated with or without GC-1 for 21 days. Rectal temperature during exposure was to 4C (n = 4).
(B) DIO Ucp1/ mice and Ucp1+/+ littermate controls were treated with GC-1 or vehicle for 14 days. Rectal temperature was measured before and after 24-hr
cold exposure (4C) (n = 5–6).
(C) Norepinephrine content in BAT and scWAT of GC-1 treated and untreated ob/ob mice (n = 6).
(D–H) Male C57Bl6 mice housed at thermoneutrality were administered GC-1 (0.3 mg/kg) or vehicle via i.p. injection for 14 days (n = 5–6). Energy expenditure at
1- min intervals (D) and day-night averages (E) were measured by indirect calorimetry. The rectal body temperature (F), thermogenic gene expression (G), and
UCP1 immunohistochemistry in scWAT (H) are shown. Scale bar, 100 mm.
(I–M) Male ob/ob mice were treated with GC-1 (0.3 mg/kg) or propranolol (Prop, 20 mg/kg) alone or together for 21 days (n = 4–5). The metabolic rate (I and J),
body temperature (K), UCP1 staining of scWAT sections (L), and thermogenic gene expression in scWAT (M) are shown. Scale bar, 100 mm.
(N) SVFs differentiated in the presence of GC-1 or vehicle were pretreated with 50 mM H-89 for 1 hr, followed by 1 uM norepinephrine (NE) for 4 hr (n = 4).
Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. yp < 0.05 comparison before versus after cold challenge. See also Figure S4.
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activation by GC-1 not only induces genes involved in thermo-
genesis but also elicits a functional increase in the metabolic
rate of white adipocytes. That UCP1 is required for the thermo-
genic effects of GC-1, despite all evidence suggesting a lack
of BAT involvement in this process, firmly implicates WAT in
mediating the thermogenic actions of GC-1 and links WAT
browning to the observed increase in systemic metabolism.
That GC-1 increases metabolic rate in vitro and in vivo demon-
strates that the compound not only induces the expression of
thermogenic genes but also activates the program of adaptive
thermogenesis. Since this program is normally controlled by
b-AR stimulation, it suggested that either SNS outflow to WAT
was increased with GC-1 or the compound lessened the
threshold for activation. Our data suggest the latter, that TR ag-
onism inwhite adipocytes elicits thermogenesis despite reduced
b-AR stimulation and establishes TR agonists as a class of
browning agent. These data also suggest that GC-1 reduces
SNS stimulation of BAT, likely as a compensatory response to
the increased thermogenic potential of scWAT. Although GC-1
appears to reduce SNS outflow to adipose tissues, the increased
body temperature of treated mice reveals that that the com-
pound does also affect the central regulation of thermal set-
point. Thus, the systemic effects of GC-1 likely stem from a com-
bination of central and peripheral actions of the compound. That
many of GC-1’s effects are lost or reduced in the absence of
Ucp1, such as the increased cold tolerance observed in ob/ob
mice, suggests that these particular effects result from direct
Ucp1-dependent peripheral actions. Somewhat surprisingly,
despite the observed functional differences, GC-1-induced
gene expression in white adipocytes was nearly identical in
Ucp1/ and Ucp1+/+ mice and cells (Figure 3H), indicating
that GC-1 treatment of Ucp1/ mice dissociates cellular
changes in white adipocytes, such as mitochondriogenesis
and lipolysis, from Ucp1-dependent thermogenesis. This type
of WAT remodeling has been suggested to mediate beneficial
Ucp1-independent effects of WAT browning (Ukropec et al.,
2006), and future studies in Ucp1/ mice may show brown-
like adipocyte remodeling affects systemic metabolic parame-
ters including fat distribution, serum lipid levels, and insulin
sensitivity. Further studies, particularly those involving Ucp1/
mice, which are under considerable thermal stress at ambient
temperatures, should also be performed at thermoneutrality to
minimize central sympathetic involvement and quantitatively
assess the contribution of peripheral Ucp1 induction to the
observed metabolic effects.
Not all TR agonists share the ability to induceWAT browning at
the magnitude observed with GC-1. It was previously thought
that differential effects of TR agonists stemmed from a preferen-
tial affinity for either the TRa or TRb isoform of the receptor. How-
ever, the discovery that the OATP1 and MCT families of trans-
porters are involved in transporting endogenous and synthetic
thyroid hormones has led to an appreciation that tissue selec-
tivity, mediated by these transporters, is also a key contributor
to the differential effects of diverse TR agonists (Meyer zu
Schwabedissen et al., 2011; Visser et al., 2011). The greater ef-
ficacy of GC-1 at inducing browning relative to KB2115, despite
both ligands being TRb selective, suggests to us that tissue se-
lective uptake is likely responsible for the compounds’ capacityCell Repto induce browning and offers a potential route to developing
improved browning agents.
While these data demonstrate clearly that TR activation can
pharmacologically induce WAT browning and thermogenesis,
the physiological relevance of this effect is not yet obvious.
Although thyroid hormone excess is clearly implicated in thermo-
genesis, the mechanistic basis for thyroid thermogenesis has
never been clear. In vitro, thyroid hormone and other TR ago-
nists, including GC-1, induce thermogenic genes in brown adi-
pocytes and are, in fact, necessary for brown adipocyte cell cul-
ture (Guerra et al., 1998; Martinez de Mena et al., 2010). In vivo,
however, thyroid thermogenesis is generally accompanied by
decreased BAT activity, indicating that the observed thermogen-
esis must originate from tissues other than BAT (Abelenda and
Puerta, 1992; Sato et al., 1986). Thus, the decreased BAT activity
observed with GC-1 treatment is likely not a cell-autonomous ef-
fect of the compound, but is instead a result of decreased SNS
innervation of BAT. Is WAT browning an unappreciated compo-
nent of thyroid thermogenesis? As T3 can also induce browning
in vitro (Lee et al., 2012;Wang et al., 2014), it is certainly possible.
However, since T3 appears to be much less effective at promot-
ing browning than GC-1, further studies will be necessary to
determine whether browning is a major contributor to the ther-
mogenesis that accompanies hyperthyroid states or simply an
ancillary effect.
In conclusion, TR activation by the synthetic agonist GC-1 in-
duces a genetic program of BAT-like thermogenesis in subcu-
taneous white adipocytes in vitro and in vivo. WAT browning co-
incides with increased thermogenic capacity that is sufficient to
restore cold tolerance to cold-intolerant mice, which we suggest
demonstrates the profound pharmacological potential of TR-
mediated browning. Given that GC-1 can increase adipocyte
metabolism in a cell-autonomous fashion and has been shown
previously to evoke weight loss in non-human primates (Grover
et al., 2004), we believe there is strong potential that these results
could be translated to man.
EXPERIMENTAL PROCEDURES
Animals
Ucp1/ mice (Jackson Laboratories), C57Bl/6 mice (Harlan), and ob/ob mice
(Harlan) were housed at 22C in a 12 hr light-dark cycle and fed ad libitum
chow. At 6 weeks of age, C57Bl/6 and Ucp1/ mice were fed a 60% kcal
high-fat diet (Research Diets) for 8–10 weeks, unless otherwise noted. For
thermoneutrality, mice were individually housed at 30C in an environment-
controlled chamber. All animal experiments were approved by the Institutional
Animal Care and Use Committee of Houston Methodist Research Institute.
Treatment
GC-1 was administered via i.p. injections (0.3 mg/kg/d GC-1) or admixed in
chow (3 mg/kg diet). For b-AR antagonist studies, propranolol (20 mg/kg)
was co-administered with GC-1 (0.3 mg/kg) or propranolol alone via i.p. injec-
tion for 21 days. For KB2115 treatment, ob/ob were fed KB2115 admixed in
chow (3 mg/kg-diet) for 21 days. Control groups received appropriate vehicle
solutions or diets identical to treatment groups.
BAT Denervation
BAT denervation surgery was performed on ob/ob and C57Bl/6 mice at 3 to
4 weeks of age. Mice were anesthetized with isoflurane and body temperature
was maintained with a warming pad. Intrascapular BAT lobes were elevated
from the underlying cervical and scapular caudally to separate it from theorts 13, 1528–1537, November 24, 2015 ª2015 The Authors 1535
surrounding muscle and expose sympathetic nerves. The five intercostal
nerves of each lobe were isolated, and a section of each nerve was removed
without damaging the vasculature. The sham procedure was identical except
nerves were not transected.
Primary Cell Culture
Mouse preadipocytes were collected from inguinal fat depots of 4-week old
C57Bl6 or Ucp1/ mice. Briefly, tissues were digested at 37C for 45 min
with collagenase I (1.5 mg/ml) and dispase (2.5 mg/ul) and then filtered through
100- and 40-mm cell strainers. The stromal vascular cells were cultured in
DMEM/F-12 containing 10% fetal bovine serum (FBS) (Sigma). Confluent cells
wereexposed toadipocytedifferentiationmedia for48hr and received freshme-
dia containing insulin every 2 days. For TR agonist treatment, cells were treated
with 100 mM of GC-1 or vehicle for the times indicated. For PKA inhibition, cells
were pretreated with H-89 for 1 hr followed by norepinephrine (NE) for 4 hr.
Statistical Analysis
Data are presented asmean ±SEM. A p value of less than 0.05 was considered
significant. Student’s t test was used for pairwise comparisons.
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